News Column

Patent Issued for Utilization of Stents for the Treatment of Blood Borne Carcinomas

July 9, 2014

By a News Reporter-Staff News Editor at Biotech Week -- A patent by the inventor Felder, Mitchell S. (Hermitage, PA), filed on November 11, 2009, was published online on June 24, 2014, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents (see also Marv Enterprises, LLC).

Patent number 8758287 is assigned to Marv Enterprises, LLC (Hermitage, PA).

The following quote was obtained by the news editors from the background information supplied by the inventors: "The treatment of blood borne cancers with conventional therapies such as cytotoxic drugs and irradiation has not been as effective as desired. A major drawback has been that such treatments can destroy healthy as well as diseased cells.

"One way to kill cancer cells is through the natural phenomenon of apoptosis, also referred to as programmed cell death. Apoptosis is a critical homeostatic mechanism in the body to maintain the necessary proportion of cell proliferation and cell death. The problem with conventional agents that induce apoptosis is that these agents also may have deleterious systemic effects."

In addition to the background information obtained for this patent, NewsRx journalists also obtained the inventor's summary information for this patent: "The present invention utilizes an article and method to kill blood borne cancer cells using extracorporeal dialysis. More particularly, the invention relates to an article and method to treat a patient afflicted with a blood borne cancer, such as leukemia, by filtering the patient's blood through a filter comprising at least one extracorporeal stent treated with an antineoplastic agent. The invention induces apoptosis of leukemic cells or carcinoma cells in the patient's bloodstream.

"The device can induce apoptosis of carcinoma cells and is substantially non-toxic to the patient. The method pumps a patient's blood through a filter comprising at least one stent treated with an antineoplastic agent. The method can greatly reduce the risk of deleterious side effects and morbidity and mortality to the patient.

"The stent of the present invention includes an interior wall that defines a channel. The channel is configured to induce apoptosis of cancer cells. The channel can contain packing material. At least a portion of the channel can be coated with a coating comprising an antineoplastic agent.

"The present invention can enhance the longevity and quality of life of patients by inducing apoptosis of the blood borne carcinoma cells by using a non-toxic filter comprising stents that induce apoptosis of cancer cells. The removal of blood borne carcinoma cells from the body of a patient can reduce complications and lessen the frequency of hospital stays and/or the need for chemotherapy. These and other aspects of the present invention will be more fully understood from the following detailed description of the invention and the drawing."

URL and more information on this patent, see: Felder, Mitchell S.. Utilization of Stents for the Treatment of Blood Borne Carcinomas. U.S. Patent Number 8758287, filed November 11, 2009, and published online on June 24, 2014. Patent URL:

Keywords for this news article include: Antineoplastics, Cancer, Therapy, Oncology, Carcinoma, Marv Enterprises LLC.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters